Pakistan · Delayed Price · Currency is PKR Citi Pharma Statistics
Total Valuation
Citi Pharma has a market cap or net worth of PKR 18.08 billion. The enterprise value is 21.32 billion.
| Market Cap | 18.08B |
| Enterprise Value | 21.32B |
Important Dates
The last earnings date was Wednesday, April 29, 2026.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | Oct 17, 2025 |
Share Statistics
Citi Pharma has 228.46 million shares outstanding. The number of shares has decreased by -0.07% in one year.
| Current Share Class | 228.46M |
| Shares Outstanding | 228.46M |
| Shares Change (YoY) | -0.07% |
| Shares Change (QoQ) | -0.36% |
| Owned by Insiders (%) | 38.66% |
| Owned by Institutions (%) | 6.42% |
| Float | 135.64M |
Valuation Ratios
The trailing PE ratio is 16.49 and the forward PE ratio is 18.84.
| PE Ratio | 16.49 |
| Forward PE | 18.84 |
| PS Ratio | 1.31 |
| PB Ratio | 1.65 |
| P/TBV Ratio | 1.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.39, with an EV/FCF ratio of -28.75.
| EV / Earnings | 19.44 |
| EV / Sales | 1.54 |
| EV / EBITDA | 9.39 |
| EV / EBIT | 10.23 |
| EV / FCF | -28.75 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.31 |
| Quick Ratio | 0.59 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 1.57 |
| Debt / FCF | -4.81 |
| Interest Coverage | 5.66 |
Financial Efficiency
Return on equity (ROE) is 13.28% and return on invested capital (ROIC) is 9.93%.
| Return on Equity (ROE) | 13.28% |
| Return on Assets (ROA) | 8.02% |
| Return on Invested Capital (ROIC) | 9.93% |
| Return on Capital Employed (ROCE) | 18.54% |
| Weighted Average Cost of Capital (WACC) | 6.69% |
| Revenue Per Employee | 26.07M |
| Profits Per Employee | 2.07M |
| Employee Count | 531 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 2.65 |
Taxes
In the past 12 months, Citi Pharma has paid 581.60 million in taxes.
| Income Tax | 581.60M |
| Effective Tax Rate | 34.66% |
Stock Price Statistics
The stock price has increased by +8.17% in the last 52 weeks. The beta is 0.44, so Citi Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +8.17% |
| 50-Day Moving Average | 77.48 |
| 200-Day Moving Average | 85.92 |
| Relative Strength Index (RSI) | 53.22 |
| Average Volume (20 Days) | 2,957,594 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Citi Pharma had revenue of PKR 13.84 billion and earned 1.10 billion in profits. Earnings per share was 4.80.
| Revenue | 13.84B |
| Gross Profit | 2.56B |
| Operating Income | 2.08B |
| Pretax Income | 1.68B |
| Net Income | 1.10B |
| EBITDA | 2.27B |
| EBIT | 2.08B |
| Earnings Per Share (EPS) | 4.80 |
Balance Sheet
The company has 324.19 million in cash and 3.57 billion in debt, with a net cash position of -3.24 billion or -14.19 per share.
| Cash & Cash Equivalents | 324.19M |
| Total Debt | 3.57B |
| Net Cash | -3.24B |
| Net Cash Per Share | -14.19 |
| Equity (Book Value) | 10.95B |
| Book Value Per Share | 48.11 |
| Working Capital | 2.34B |
Cash Flow
In the last 12 months, operating cash flow was -690.96 million and capital expenditures -50.75 million, giving a free cash flow of -741.71 million.
| Operating Cash Flow | -690.96M |
| Capital Expenditures | -50.75M |
| Depreciation & Amortization | 181.06M |
| Net Borrowing | 548.54M |
| Free Cash Flow | -741.71M |
| FCF Per Share | -3.25 |
Margins
Gross margin is 18.50%, with operating and profit margins of 15.06% and 7.92%.
| Gross Margin | 18.50% |
| Operating Margin | 15.06% |
| Pretax Margin | 12.13% |
| Profit Margin | 7.92% |
| EBITDA Margin | 16.37% |
| EBIT Margin | 15.06% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 4.34%.
| Dividend Per Share | 3.50 |
| Dividend Yield | 4.34% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 72.92% |
| Buyback Yield | 0.07% |
| Shareholder Yield | 4.41% |
| Earnings Yield | 6.07% |
| FCF Yield | -4.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 18, 2021. It was a forward split with a ratio of 1.1.
| Last Split Date | Oct 18, 2021 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |